Denmark: Eye Disease After Weight Loss Injection - Compensation - Denmark Compensates Patients After Ozempic and Wegovy Cause Vision Loss
Four Danish patients have received state compensation after suffering severe vision damage linked to popular diabetes and obesity drugs. The cases involve Wegovy and Ozempic, both manufactured by Novo Nordisk. Authorities describe the situation as complex due to the medications' recent introduction and patients' prior health conditions.
The patients developed NAION, a rare eye disorder that often leads to permanent vision loss. This condition has been identified as a very rare side effect of semaglutide, the active ingredient in both Wegovy and Ozempic. The European Medicines Agency (EMA) confirmed the connection but stressed that NAION may affect only one in 10,000 users.
The compensation payouts mark the first official recognition of NAION as a side effect in these cases. Patients using Wegovy or Ozempic are now urged to watch for vision changes and act quickly if symptoms appear. The EMA’s warning underscores the importance of prompt medical attention for those at risk.
